Caris Life Sciences,�Inc. CAI
31.98
(0.29)
(0.90%)
as of 25 Sep
- Market cap
- $9.1B
- P/E
- 85.1×
Follow CAI
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+6 more TTM periods Free account |
0.00% | 0.00% | 45.75% | 15.45% | |
| (139.72%) | (95.58%) | (75.00%) | 7.39% | ||
ROIC |
(66.54%) | 18.05% | 44.67% | 49.95% | |
Return on Tangible Assets |
(82.65%) | (57.61%) | (45.74%) | 8.39% | |
Average Days of Receivables |
15.70 | 50.41 | 36.41 | 43.11 | |
Free Cash Flow per Share |
(0.05) | 0.40 | 0.44 | 0.44 | |
Free Cash Flow |
(14.01) | 66.90 | 123.46 | 123.96 | |
Capital Expenditures |
(13.46) | (16.26) | (23.91) | (44.60) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(0.03%) | 4.73% | 8.19% | 9.48% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 10.15 | 11.80 | |
Accounts Payable Turnover |
0.00 | 0.00 | 5.82 | 5.23 | |
Inventory Turnover |
0.00 | 0.00 | 4.90 | 3.65 | |
Average Days of Payables |
41.01 | 52.44 | 89.76 | 104.53 | |
Days of Inventory on Hand |
69.72 | 85.11 | 98.10 | 150.49 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
15.69% | 12.51% | 12.11% | 11.84% | |
Selling, General and Administrative Expense of Revenue |
59.51% | 48.33% | 44.67% | 42.34% | |
Share Based Compensation of Revenue |
9.88% | 8.62% | 7.85% | 6.58% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | (0.15) | (0.34) | 2.09 | |
Depreciation/Fixed assets |
0.65 | 0.56 | 0.41 | 0.28 | |
Capex/Depreciation |
(0.32) | (0.46) | (0.70) | (1.67) | |
Revenue per Share |
2.20 | 4.86 | 3.21 | 3.50 | |
Operating CF per Share |
0.00 | 0.50 | 0.52 | 0.60 | |
Capex per Share |
(0.05) | (0.10) | (0.08) | (0.16) | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.05 | |
Net Profit Margin |
(110.81%) | (66.25%) | (48.04%) | 8.15% |
Columns are period end dates